Market Overview

Tmunity Names Graeme Bell as Chief Financial Officer and Executive Vice President


Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics
company focused on saving and improving lives by delivering the full
potential of next-generation T cell immunotherapy, today announced the
appointment of Graeme Bell as Chief Financial Officer (CFO) and
Executive Vice President. Mr. Bell formerly served in CFO roles at
Intellia Therapeutics, Anacor Pharmaceuticals, and at Merck & Co., Inc.
in US and UK operations.

"Graeme's broad and deep experience in the biopharma industry — and his
distinguished track record of leadership in finance, commercial
operations and investor relations — will be invaluable to Tmunity as we
invest in business growth and advance our pipeline of next-generation T
cell immunotherapies," said Usman "Oz" Azam, MD, President and Chief
Executive Officer of Tmunity. "Graeme's extensive knowledge in finance
and proven success in deal-making will be a tremendous asset to Tmunity
as we continue to create and pursue strategic business opportunities
that align with our vision."

In his role at Tmunity, Mr. Bell will be responsible for all aspects of
the company's financial operations, including relationships with the
capital markets. He will also oversee IT and other operational aspects,
and work closely with the University of Pennsylvania and external

"Tmunity is one of the most exciting companies I have encountered, with
the potential to change the course of treatment for many cancers and
other serious diseases," said Mr. Bell. "I look forward to joining the
Tmunity management team and working with an esteemed group of colleagues
who have unrivaled cell and gene therapy expertise and are committed to
developing the next generation of personalized therapies for patients."

During his tenure with Intellia Therapeutics, Mr. Bell held the position
of CFO and was also responsible for operations, IT and investor
relations. Prior to Intellia, he was CFO and oversaw operations at
Anacor Pharmaceuticals. Mr. Bell also previously served as CFO at Merck
& Co., Inc. in US and UK operations and held finance positions of
increasing responsibility in manufacturing, commercial and corporate

"I am delighted that Graeme has joined the Tmunity management team. His
diverse background in finance across big pharma and small biotech,
coupled with his global expertise in capital markets, comes at the right
time as we accelerate investment into our clinical research programs and
begin commercial planning," said Carl H. June, MD, Director of the
Center for Cellular Immunotherapies at the Perleman School of Medicine,
and Director of the Parker Institute for Cancer Immunotherapy at the
University of Pennsylvania.

Mr. Bell holds a Master of Business Administration degree from the
University of Durham (UK) and is a Fellow of the Chartered Institute of
Management Accountants.

About Tmunity Therapeutics

Tmunity is a private clinical-stage biotherapeutics company focused on
saving and improving lives by delivering the full potential of
next-generation T cell immunotherapy to patients with devastating
diseases. Integrating a foundational collaboration with the University
of Pennsylvania (Penn) and the groundbreaking scientific, clinical and
manufacturing expertise and demonstrated track record of its founders
(Carl June, MD; Bruce Blazar, MD; Bruce Levine, PhD; Yangbing Zhao, MD,
PhD; Jim Riley, PhD; and Anne Chew, PhD), Tmunity represents a new
center of gravity in translational T cell medicine. The company is
developing a diversified portfolio of novel treatments that exhibit
best-in-class control over T cell activation and direction in the body,
with an initial focus in cancer with two programs currently in the
clinic. Headquartered in Philadelphia, Tmunity utilizes laboratories and
production facilities at Penn and its own dedicated cGMP manufacturing
facility in Norristown, PA, to pursue process improvement and production
scale-up in support of clinical development of its T cell therapies. For
more information, visit

View Comments and Join the Discussion!